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ABSTRACT
NLRs (nucleotide-binding domain leucine-rich repeat proteins or NOD-like 
receptors) are regulators of inflammation and immunity. A subgroup of NLRs and 
the innate immune receptor, AIM2 (absent-in-melanoma 2), can induce the assembly 
of a large caspase-1 activating complex called the inflammasome. Other NLRs 
regulate key signaling pathways such as NF-kB and MAPK. Since inflammation is a 
central component of colorectal cancer (CRC), this work was undertaken to analyze 
NLR and AIM2 expression in human CRC by combining bioinformatics analysis and 
experimental verification using clinical tissue samples. Additional experiments 
analyzed the association of (i) gene expression and cancer staging, and (ii) gene 
expression among inflammasome components. 
     Ten public CRC datasets from the Oncomine® Platform were analyzed. Genes 
analyzed include NLRP1, NLRP3, NLRP6, NLRP12, NLRC3, NLRC4, NLRC5, NOD1, NOD2 
and AIM2. Additionally, forty case-matched cancer samples and adjacent healthy 
control tissues isolated from a cohort of Chinese CRC patients were profiled. 
Three patterns of gene expression in CRC are shown. The expression of NLRC3, 
a checkpoint of inflammation, and the inflammasome components NLRP1, NLRP3, 
NLRC4 and AIM2 were reduced in CRC. NOD1 and NOD2 expression was increased in 
CRC, while NLRC5, NLRP6 and NLRP12 showed little difference compared to controls. 
Reduced expression of NLRC3 in CRC was verified in all available databases analyzed 
and confirmed with our patient cohort. Furthermore, the extent of NLRC3 and AIM2 
gene reduction was correlated with cancer progression. This report reveals the 
potential value of NLR and AIM2 genes as biomarkers of CRC and cancer progression.
INTRODUCTION
Inflammation is one of the hallmarks of cancer. 
Whereas acute inflammation protects against infectious 
pathogens, chronic inflammation is associated with DNA 
and tissue damage, including genetic and epigenetic 
changes leading to cancer. A common feature of 
gastrointestinal inflammatory diseases that leads to 
Oncotarget33457www.impactjournals.com/oncotarget
colorectal cancer (CRC) is the exaggerated production 
of cytokines by resident innate immune cells. These 
proinflammatory mediators stimulate the secretion of 
molecules that damage the intestinal epithelium and 
further amplify the response by recruiting and activating 
additional immune cells [1]. 
In the human intestine, trillions of bacteria interact 
with the host immune system in a complex balance 
between immune activation and tolerance. Pattern 
recognition receptors (PRRs) are essential components 
of the host immune system and significantly contribute 
to cancer pathobiology. There are at least four families 
of PRRs that have been implicated in tumorigenesis, 
including the toll-like receptors (TLRs), the NOD-like 
receptors (NLR), C-type lectin receptors (CLRs), and 
RIG-I-like receptors (RLRs). To date, the majority of 
studies assessing PRR signaling in cancer have focused on 
members of the TLR family. However, new and emerging 
findings in murine models have revealed a significant 
role for members of the NLR family in contributing to 
a variety of hallmarks associated with cancer including 
inflammation, cell death, tumor growth, angiogenesis, 
invasion, and metastasis [2]. 
There are 22 NLR members in humans and 34 
members in mice [2]. A functional sub-group of NLRs 
has been identified as driving formation of a multi-protein 
complex termed the inflammasome [3]. The inflammasome 
is composed of an NLR that recognizes either a specific 
repertoire of pathogen associated molecular pattern 
(PAMP) or autologous damage associated molecular 
pattern (DAMP) molecules, the adaptor protein ASC, 
and pro-caspase-1. These subunits continue to multiplex, 
ultimately resulting in the maturation and activation 
of caspase-1, which subsequently drives the cleavage 
and activation of IL-1 and IL-18 [3]. The complex roles 
of inflammasome activation in cancer development or 
therapy have received much attention. In addition to NLR-
based inflammasomes, AIM2, a member of the AIM2-like 
receptors (ALRs) that contain pyrin and hin domains, is 
crucial for inflamamsome activation induced by double-
stranded DNA. AIM2 reduced Akt activation and tumor 
burden in colorectal cancer models, while an Akt inhibitor 
reduced tumor load in Aim2-/- mice [4]. In the DSS colitis 
model and DSS-AOM colitis associated colon cancer 
murine models, several inflammasomes including NLRP3, 
NLRP6 and NLRC4 have been found to protect against 
dysplasia and hyperplasia in the colon.  
CRC is one of the major causes of morbidity and 
mortality in developed countries. It is ranked the third 
most common cancer among males and females in the 
United States according to Cancer Statistics for 2015. 
Recent data have shown that the incidence rates of CRC 
has rapidly increased in China [5]. As a majority of 
patients are still diagnosed at a late stage, biomarkers that 
may allow early diagnosis are crucial [5]. Inflammatory 
molecules represent a possible source of CRC biomarkers, 
because the molecular pathobiology of CRC implicates 
pro-inflammatory conditions as promoting factors 
in the malignant progression of the tumor, invasion, 
and metastasis. It is well known that patients with 
inflammatory bowel disease such as Crohn’s disease and 
ulcerative colitis are at higher risk of CRC, thus providing 
a link between inflammation and CRC [6]. Even among 
CRC that are linked to genetic mutations, contribution 
from inflammation to tumor development has been 
implicated, as shown by decreased CRC mortality with 
the regular use of nonsteroidal anti-inflammatory drugs 
(NSAIDs). These data strongly support a pro-tumorigenic 
role of inflammation in colon cancer [6].
Thus far, there are multiple studies of NLRs and 
AIM2 in animal CRC models [4, 7, 8], but there is a 
paucity of papers that have analyzed these genes in human 
CRC. In this report, we performed an extensive analysis 
of NLRs and AIM2 in human CRC by combining the 
bioinformatics analysis of ten independent, publically 
available databases with experimental validation using 
tissue samples from CRC patients. The study shows 
that NLRC3, an NLR protein that has been reported to 
negatively regulate inflammatory cytokines and NF-
kB activity [9, 10], was reduced in CRC relative to 
controls in all public databases analyzed and this finding 
was substantiated in primary CRC patient samples. 
This indicates the robustness of data regarding reduced 
NLRC3 expression in CRC. In addition, the expression of 
inflammasome NLRs and AIM2 in CRC was significantly 
lower than normal controls in the TCGA database, 
suggesting that these genes could be important for 
maintaining tissue homeostasis against tumorigenesis. 
An analysis of primary patient samples showed that the 
expression of a major inflammasome NLR, NLRP3, was 
reduced in primary CRC samples. Additional correlative 
analyses of gene expression with cancer stages, tumor 
anatomic locations and other components within the 
inflammasome pathway were conducted. Based on this 
broad analysis, NLRC3 and several inflammasome genes 
may represent valuable candidate biomarkers for CRC 
screening. 
RESULTS 
Expression levels of NLRs and AIM2 in colorectal 
cancer culled from the Oncomine® Platform
The Oncomine® Platform (http://www.oncomine.
org) is an online collection of microarrays where data are 
analyzed and standardized uniformly thus allowing for an 
easy comparison across studies. We initially analyzed the 
expression levels of NLRP1, NLRP3, NLRC3, NLRC4, 
NLRC5, NLRP6, NLRP12, NOD1, NOD2 and AIM2 
using the Oncomine® Platform CRC database to compare 
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Figure 1: Analysis of microarray gene expression data for NLRs and AIM2 in the TCGA database. The raw data was 
exported from the TCGA CRC database, with representations of 22 samples from healthy control and 215 samples from CRC. A. Expression 
levels of NLRP1, NLRP3, NLRC3, NLRC4 and AIM2 were significantly decreased in human colorectal cancer; B. NOD1 and NOD2 had 
significantly higher levels of expression in CRC; C. NLRC5, NLRP6 and NLRP12 expression was slightly reduced in CRC but statistical 
significance was not reached. Data are expressed as mean ± SEM. Log2 median- centered ratio expression. Unpaired Mann-Whitney test 
was used to evaluate the significance of differential mRNA expression levels of candidate genes. ** indicates P < 0.01; **** indicates P < 
0.0001; ns, no statistical difference.
Table 1: Statistical analysis of NLRs and AIM2 expression in CRCs from different anatomical localizations.
TCGA database in the Oncomine® Platform was analyzed. Fold change was calculated by taking the average of 102 colon 
adenocarcinoma, 60 rectal adenocarcinoma or 24 cecum adenocarcinoma samples compared with 22 normal controls. Results 
are expressed as means between the controls and CRC groups in a differential expression analysis using the Oncomine® 
Platform.
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healthy versus cancer tissues. Among the genes analyzed, 
all except for NLRC3 have at least one paper supporting 
their function in inflammasome activation, leading to 
caspase-1 activation to process pro-IL1-β and pro-IL-18 
[11]. However, several of these genes have been reported 
to display other functions, and some cases the other 
functions are the more consistently observed ones. For 
example, the main function of NLRC5 is regulating class 
I Major Histocompatibility Complex (MHC) genes [12], 
while NOD1/NOD2 proteins are primarily required for the 
positive regulation of NF-κB and MAPK [13]. NLRP6 and 
NLRP12 have been found to attenuate NF-kB and MAPK 
in models of colitis and CRC [14-17], NLRC3 has been 
shown to act as a negative regulator of TLR and DNA-
induced cytokine production [9, 10]. 
Ten databases are listed in Materials and Methods. 
These databases have different number of patients 
and contain different clinical information. We choose 
to analyze the Cancer Genome Atlas (TCGA) which 
contained the most comprehensive colon database as a 
starting point for our analysis [18]. Analysis of the TCGA 
database showed that the expression of analyzed genes 
can be grouped into three patterns. In the first one, the 
expression levels of NLRP1, NLRP3, NLRC3, NLRC4 
and AIM2 in CRC were significantly lowered in CRC 
than in healthy controls (Figure 1A, data summarized in 
Table 1). In the second group, an opposite pattern was 
observed with NOD1 and NOD2 (Figure 1B and Table 
1), where these genes were significantly higher in CRC 
than controls. In a final group, NLRC5, NLRP6 and 
NLRP12 expression was not statistically different from 
controls (Figure 1C and Table 1). Table 1 also shows gene 
expression comparisons between CRC and controls in 
colon adenocarcinoma, rectal adenocarcinoma and cecum 
adenocarcinoma. No distinct differences were observed 
among these different cancers, indicating that levels and 
patterns of expression are comparable amongst various 
colorectal cancers at different anatomic locations.
Expression levels of NLRs and AIM2 in various 
stages of colorectal cancer progression
Next we analyzed the expression levels of NLRs 
and AIM2 at various stages of cancer progression in the 
TCGA database. CRC cases were staged according to the 
AJCC (American Joint Committee on Cancer) staging 
system, which also is known as the TNM (tumor-node-
metastasis) system. In Stage I tumor has spread beyond 
the inner lining of the colon to the second and third layers 
and involves the inside wall of the colon. Stage II tumor 
is larger and extends through the muscular wall of the 
colon, while Stage III cancer has spread outside the colon 
to one or more lymph nodes. Finally, Stage IV cancer has 
metastasized to other areas of the body, such as the liver or 
lung [19]. Data presented in Figure 2A and 2B demonstrate 
that NLRC3, AIM2, NLRP1, NLRP3, NLRC4, NOD1 
and NOD2 displayed statistically different levels of 
expression in healthy control vs. various CRC stages. 
Similar to Figure 1, the expression of NLRC3, AIM2, 
NLRP1, NLRP3 and NLRC4 was reduced in all stages 
of CRC relative to healthy controls, while the expression 
of NOD1 and NOD2 were higher in CRC compared to 
controls. NLRC3 and AIM2 (Figure 2A) were the only 
two genes that showed statistical difference between stage 
IV CRC and stages I-III CRC, wherein their expression in 
stage IV CRC was significantly lower than the other stages 
of CRC. These results suggest that NLRC3 and AIM2 
may be useful as biomarkers of cancer progression. By 
contrast, levels of NLRC5, NLRP12 and NLRP6 did not 
differ between stages of cancer progression (Figure 2C). 
    In sum, these results obtained from the TCGA 
database indicate that across tumor stages, NLRP1, 
NLRP3, NLRC3, NLRC4 and AIM2 expression in CRC 
tissues was significantly less than healthy controls. In 
contrast, NOD1 and NOD2 expression was significantly 
higher than controls, while NLRP6, NLRP5 and NLRP12 
expression was not statistically different from controls. 
Among the genes analyzed, AIM2 and NLRC3 expression 
was significantly reduced in stage IV CRC compared to 
the earlier tumor stages.
Expression of NLRs and AIM2 in human 
colorectal cancer FFPE clinical samples from 
China
Next, we compared forty freshly isolated CRC 
and forty adjacent normal FFPE tissues obtained from a 
Chinese patient cohort for the expression of NLRs and 
AIM2 by Q-RT-PCR. As shown in Figure 3A levels of 
NLRC3 and NLRP3 were significantly reduced in CRC 
while levels of NLRP6, NLRP12 and NLRC5 (Figure 3B) 
were not significantly different between CRC and controls. 
These data are in agreement with the TCGA database 
presented in Figure 1. However, expression levels of 
NLRC4, AIM2, NOD1, NOD2 and NLRP1 (Figure 
3C) in FFPE CRC and adjacent normal controls were 
not significantly different and did not correlate with the 
TCGA database presented in Figure 1. There are several 
caveats that could account for the difference between the 
TCGA database and our patient cohort. Some of the genes 
were detected at a very low level. For example, 13 out 
of 40 (32.5%) FPPE human samples had undetectable 
levels of NLRP1, and this low level of expression made 
the analysis definitely less reliable. Another caveat is 
that the experimental FPPE samples represent a small 
patient cohort. Finally, while the FFPE samples were 
obtained from a Chinese cohort, the ten Oncomine® 
Platform databases were collected from patients outside 
of China, which may reveal groups with different genetic 
variations. As an illustration, while NOD2 has been 
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Figure 2: Correlation analysis comparing expression levels of NLRs and AIM2 among different stages of CRC 
progression. TNM stage information was exported from the TCGA colon database. A. NLRC3 and AIM2 showed statistically different 
levels of expression between healthy control and various CRC stages of cancer progression, where stage IV exhibited significantly lower 
expression of these two genes than stages 1-3. B. NLRP1, NLRP3, NLRC4, NOD1 and NOD2 exhibited statistically different levels of 
expression between healthy control and all four stages of CRC.  C. Levels of NLRC5, NLRP12 and NLRP6 expression among control and 
cancer stages 1-4 were not significantly different. Data were presented as means ± SEM. *P < 0.05; **P < 0.01; **P < 0.001****P < 0.0001
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strongly associated with Crohns’ disease in patients from 
the Western world, this has not been observed among 
Asian patients [20-22]. This observation is in agreement 
with our own analyses where NOD2 levels of expression 
were statistically higher in CRC based on multiple 
databases (Figure 1B), but yet it did not reached statistical 
significance in FFPE samples from the Chinese cohort 
(Figure 3C). In summary, the bioinformatics analyses 
of the TCGA database and the experimental analysis 
of clinical samples from China both showed reduced 
expression of NLRC3 and NLRP3 in CRC samples.  
The expression of inflammasome genes and 
correlation with NLRs and AIM2
One of the most important functions of the NLR 
and ALR family is to serve as central components of an 
inflammasome. Inflammasome is composed of an NLR 
or AIM2, which serves as the sensor or receptor that 
recognizes PAMPs or DAMPs, the adaptor protein ASC 
and pro-caspase 1 Inflammasome activation depends on 
the expression of the multiple inflammasome protein 
components in the same cell. ASC and caspase-1 are found 
in many tissues and cell types and have been shown to 
protect against colitis-associated CRC in mice [23]. IL-
Figure 3: Expression of NLRs and AIM2 in human CRC FFPE samples (n = 40). The quantitative RT- PCR data were obtained 
by the comparative CT method (2
-ΔΔCT). A. The expression of NLRC3 and NLRP3 was significantly reduced in CRC. B. NLRP6, NLRP12 
and NLRC5 expression was not significantly different between CRC and healthy controls. Results shown in A. and B. are congruent with 
the TCGA database presented in Figure 1. C. NLRC4, AIM2, NOD1, NOD2 and NLRP1 expression in FFPE CRC and adjacent normal 
controls were not significantly different. This data does not correlate with the TCGA database. The RT-PCR results are converted to a log2 
scale. Data are expressed as mean ± SEM. Wilcoxon matched-pairs signed rank test was used to evaluate the significance of differential 
mRNA expression levels of candidate genes. *P < 0.05; **P < 0.01; **P < 0.001 ****P < 0.0001, and ns indicates the lack of a statistical 
difference. NLRP1 was only detected in 27 samples. Mann-Whitney unpaired test was used to perform statistical analysis on the GraphPad 
software.
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1β mRNA expression is primarily found in myeloid cells, 
although it is also expressed by other cell types and its 
expression is enhanced in a number of cancers including 
lung, colon, melanoma, and breast. Functionally, it is 
a potent pro-inflammatory cytokine associated with 
tumor growth and angiogenesis [24]. Since the analysis 
of Oncomine® Platform databases and FFPE samples 
consistently showed that NLRP3 was reduced in CRC, 
we analyzed the corollary expression of NLRP3 with the 
other inflammasome components in CRC and control 
samples. Figure 4A shows that mRNA expression of two 
inflammasome components, ASC and caspase1, and the 
downstream substrates of caspase-1, IL-1β and IL-18, in 
human FFPE CRC samples. Levels of ASC and caspase-1 
were significantly lower in human CRC samples relative 
to their healthy adjacent colon tissues. Consistent with the 
literature, the level of IL-1β was statistically elevated in 
these CRC samples. Pro-IL-18 is also cleaved by caspase-1 
into its mature form and has been reported to play both 
beneficial and detrimental roles in the progression of 
cancer [25]. However our data show that the level of IL-
18 expression was not statistically different between CRC 
and adjacent controls from this cohort. By contrast, IL-18 
was significantly reduced in the TCGA database, as was 
ASC (Figure 4B). IL-1β expression in CRC was increased 
in the TCGA database, but caspase-1 was not different. 
The difference between our patient cohort and the TCGA 
database parallels the confounding literature regarding 
IL-18 and cancer. In humans, an increase in IL-18 has 
been correlated with various types of cancer including 
ovarian carcinoma, head and neck squamous carcinoma, 
breast cancer, and others [26, 27]. However, in models of 
colitis-associated colorectal cancer IL-18 cytokine add-
back showed that IL-18 protected against tumor [28]. The 
administration of IL-18 also induced anti-tumor immunity 
in mice bearing B16 melanoma tumors expressing B7-1 
(CD80) [29]. Hence, the roles of IL-18 in cancer and 
cancer models are complex and may vary depending on 
the types of tumors and the companion therapy used to 
treat the tumor. 
Inflammasome-forming NLRs have been found 
to significantly regulate the tumor microenvironment 
by modulating cytokine production [3], and the TCGA 
database and our patient cohort showed reduced NLRP3 
expression. Thus we examined the level of NLRP3 
expression in primary CRC tissues and found that it was 
directly correlated with inflammasome components ASC, 
caspase-1, IL-1β and IL-18 (Figure 4C). By contrast, 
NLRP12 did not show a significant correlation with 
inflammasome components (Fig.4D). NLRP12 has been 
linked to inflammasome induction induced by a limited 
number of pathogens [30], but it additionally displayed 
functions beside inflammasome activation by reducing 
NF-kB and MAPK activation [15]. The lack of an 
associative expression between NLRP12 and the other 
inflammasome components may be attributed to these 
alternate functions of NLRP12. 
Analyses of NLRs and AIM2 expression in 
multiple databases
To increase the power of this analysis, we assessed 
the expression of NLRs and AIM2 in nine additional 
databases within the Oncomine® Platform. Data from 
fewer than nine total databases are shown for each gene, 
because all of these genes are missing in one or more 
databases. In short, Figure 5A shows significantly lower 
expression of NLRC3 in all databases that contained 
this gene. This is in contrast with NLRP3 expression, 
which was significantly reduced in CRC in one, elevated 
in another and not significantly different from controls 
in three other databases (Figure 5B). In addition to 
NLRC3, which showed remarkable consistency, NOD1/
NOD2 was higher in CRC in all except for one database 
(Supplementary Figure 1A and 1B), while NLRC5 
expression in CRCs was not significantly different from 
controls in all-available databases (Supplementary Figure 
2). By contrast, less consistency was observed for the 
other NLRs analyzed: NLRP1 was significantly reduced 
in two out of six databases (Supplementary Figure 3A); 
NLRC4 was significantly elevated in one but reduced in 
two databases (Supplementary Figure 3B); NLRP6 was 
significantly elevated in two but reduced in one out of 
six databases (Supplementary Figure 4A); NLRP12 was 
elevated in three out of six databases (Supplementary 
Figure 4B) and AIM2 was significantly reduced in 
two out of eight databases (Supplementary Figure 5). 
Variability across different databases could be due to 
variations in patient populations, patient selection criteria, 
patient numbers and sample collection. Conversely, the 
consistency of data collected for NLRC3, NOD1, NOD2 
and NLRC5 gene expression among all of the databases 
underscores the remarkable reproducibility and robustness 
of findings pertaining to these four genes. 
DISCUSSION
Aberrant inflammation is considered both an 
emerging hallmark of tumorigenesis and an enabling 
characteristic of cancer. During the early stages of 
tumorigenesis, an inflammatory microenvironment serves 
as an enabling characteristic to activate diverse signaling 
pathways and drive the progression of pre-malignant and 
malignant lesions toward cancer. In later stages, cancer 
cells typically acquire a diverse repertoire of defense 
mechanisms that allow cells to both passively and actively 
evade immune surveillance and elimination [31]. This 
immune system subversion is an emerging hallmark of 
cancer and serves to remove the most effective barriers 
employed by the host to defend against neoplastic, late-
stage tumor, and progression of micro-metastasis [31]. 
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Figure 4: The expression of inflammasome genes in human CRC FFPE samples and correlation with NLRs and AIM2. 
A. The expression of ASC, caspase 1, IL-1β and IL-18 in human CRC samples from our Chinese cohort. B. The expression of ASC, caspase 
1, IL-1β and IL-18 in the TCGA CRC database. C. The mRNA expression level of NLRP3 in human CRC samples was positively correlated 
with ASC, Caspase1, IL1β and IL18. The quantitative real-time PCR is graphed using 2-ΔΔCT for correlation analysis and subsequently 
converted to a log2 scale. The r and p values are indicated in the graphs. Linear regression and association analyses were generated by 
GraphPad. D. NLRP12 did not show significant correlation with inflammasome components.
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Figure 5: Analyses of NLRC3 and NLRP3 gene expression in multiple databases. A. Expression of NLRC3 was significantly 
lower in CRC in all available databases; B. NLRP3 was significantly reduced in two out of six databases, but elevated in one of the 
databases and was not significantly different in the other 3 databases. Log2 median-centered ratio expression is present for 6 different 
datasets. Box plot were generated by GraphPad, which the whiskers are drawn down to the 10th percentile and up to the 90th. Points below 
and above the whiskers are drawn as individual dots. *P < 0.05; **P < 0.01; **P < 0.001 ****P < 0.0001. ns: no statistical difference
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PRRs are essential mediators of the host immune 
response and have emerged as critical elements affecting 
multiple parts of tumor pathobiology, although their roles 
are likely complex as revealed by studies of murine models 
of cancer. NLR proteins are intracellular PRRs that sense 
microbial and non-microbial products. In CRC murine 
models, some NLRs exacerbated CRC, while others were 
thought to be essential in maintaining gut homeostasis. 
Recent characterization of NLRs has revealed several 
members that attenuate inflammation. Identifying the 
unique regulatory and signaling pathways modulated 
by these NLRs is an essential step towards the ultimate 
development of effective therapeutics targeting these 
proteins and the pathways they modulate. Characterizing 
unidentified ligands, dissecting the cell types that express 
these genes and defining their regulatory mechanisms 
should significantly improve our understanding of their 
contributions to CRC.
The expression of NLRs has not been previously 
analyzed in human CRC, but their gene expression 
in other cancers has been analyzed albeit on a limited 
scale. Mitchell et al. previously reported the association 
of genetic polymorphisms in NLRP3 and NLRP12 with 
gastric cancer in Chinese individuals [32]. Another 
study found that reduced AIM2 expression was closely 
associated with poor outcome for CRC patients [33]. 
A liver cancer study revealed reduced expression of 
NLRP3 inflammasome components in different stage of 
hepatocarcinogenesis (HCC) [34]. Finally, gene expression 
profiles of non-small cell lung cancer showed that NLRC4 
was down regulated in lung cancer tissue [35].
Our data represent an extensive analysis of both 
Oncomine® Platform and clinical CRC tissues from 
our patient cohort. The TCGA database showed that 
expression levels of multiple inflammasome proteins 
including NLRP1, NLRP3, NLRC4 and AIM2 were 
significantly reduced in human CRC relative to healthy 
controls. Further analysis showed a strong corollary 
expression of NLRP3 with ASC, caspase-1, IL-1β and IL-
18. These data support the findings in mouse CRC models, 
where deficiencies in several inflammasome genes have 
been shown to exacerbate disease outcome. In addition, 
we also showed reduced NLRP3 expression in CRC in 
both the TCGA database and our patient cohort. However 
the data were less consistent when other databases from 
the Oncomine® Platform were analyzed. 
In contrast, the reduction of NLRC3 and elevation of 
NOD1 and NOD2 expression in CRC compared to control 
healthy tissue represent the most consistent findings across 
multiple databases. NLRC3 is a negative regulator of 
innate immune signaling induced by TLR via the TRAF6 
molecule and by DNA via the STING pathway [9, 10]. It 
has not been previously evaluated in the context of any 
cancer model; however, its negative regulation of NF-κB 
signaling would be expected to attenuate tumorigenesis 
[15]. Indeed our data showed that NLRC3 expression 
was significantly reduced in all eight public databases 
analyzed, and was further reduced in samples obtained 
from our own patient cohort. NLRC3 also exhibited a 
lower level of expression in stage 4 CRC compared to 
stage 1-3 CRC, suggesting its potential role in cancer 
progression. 
In contrast to NLRC3, the expression of NLRC5, 
NLRP6 and NLR12 did not show significant differences 
between controls and CRC samples. It is interesting that 
all three of these genes have been assigned multiple 
functions, including MHC gene regulation (for NLRC5), 
NF-kB and MAPK regulation (for all three), and 
inflammasome activation (for all three). The impact of 
their possible multiple functions and how each function 
might impact CRC remain to be determined.  
Besides NLRC3, the most consistent finding among 
all databases analyzed is the elevated expression of NOD1 
and NOD2 in CRC. NOD1 and NOD2 were both increased 
in the TCGA database, our patient cohort and additional 
databases in the Oncomine® Platform. NOD1 and NOD2 
are PRRs, which recognize bacterial peptidoglycan, 
leading to the activation of NF-kB and MAPK pathways. 
NOD2 showed a strong genetic association with Crohns’s 
disease, and NOD2 polymorphisms have been associated 
with gastric cancer and gastric lymphoma induced by H. 
pylori infection [20]. In a most simplistic case, increased 
NOD1 and NOD2 in CRC could result in increased NF-
kB and MAPK signaling, thus enhancing tumorigenesis 
in CRC [21].  
In summary, various NLR family members have 
been shown to influence murine models of CRC while this 
report analyzed the expression of multiple NLRs in human 
CRC. We have done extensive analyses that revealed the 
potential value of NLR and AIM2 genes as biomarkers of 
CRC and cancer progression. Reduced expression of these 
genes showed significant correlation with major clinical 
characteristics of CRC, and a subgroup of NLRs revealed 
tumor stage-specific reduced expression. Thus, NLRs 
potentially have diagnostic values as biomarkers and 
may represent promising targets for cancer therapy and 
prevention. Understanding the mechanisms underlying the 
function of these unique NLRs will assist in the design of 
future therapeutic strategies targeting a wide spectrum of 
inflammatory diseases and cancer. Beyond colon cancer, 
NLR inflammasome activation may also play important 
roles in other types of cancer, including breast cancer, skin 
cancers, and virus-associated hepatocellular carcinoma.
MATERIALS AND METHODS
Datasets and Oncomine® Platform Bioinformatics
We used the gene search function of Oncomine® 
Platform (www.oncomine.org) to locate microarray studies 
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focusing on expression of NLRs and AIM2 in CRC. We 
used the default parameters on the site for NLRs and 
Aim2 expression analysis (threshold fold change greater 
or equal to 1.5X, p value greater or equal to IE-4 and gene 
rank in the top 10%). Data analysis was performed as 
fold change comparing normal tissue with CRC samples. 
Gene lists based on fold change were obtained from ten 
CRC datasets which were named by the convention based 
on the first author and numbers of patient (CRC/normal 
controls) as follows: Gaedcke [65/65] [36], Skrzypczak 
[81/24] [37], Hong [70/12] [38], TCGA colon cancer 
[215/22] [18], Kaiser [100/5] [39], Graudens [18/12] 
[40], Ki [50/28] [41] , Gaspar [56/22][42], Notterman 
[18/18] [43] and Sabates-Bellver [32/32][44]. Following 
the expression analysis of NLRs and AIM2 from those 
databases, results were sorted based on the p value and 
then the log -transformed median centered raw data were 
downloaded from Oncomine® Platform. The boxplots and 
dot figures were created using GraphPad software. 
Clinical specimens
The IRB was approved by the Institutional Research 
Ethics Committees in Xijing Hospital, Xi’an, China. 
Samples that were used for our analyses were numbered 
and have not included any patients’ information that is 
protected under the IRB agreement. Bio specimens were 
collected from 40 patients who were newly diagnosed 
with colon or rectum adenocarcinoma that had undergone 
surgical resection during 2014 at the Xijing Hospital in 
Xi’an, China. Detailed information characterizing patients 
used in our studies are listed in Supplementary Table 1. All 
40 colorectal cancer patients included in our studies were 
very carefully selected in the pre-screening process, where 
the H&E staining as shown in Supplementary Figure 6 
was used to confirm the tumor formation in colorectal 
samples and normal crypt formation in healthy controls.  
In addition every patient has been thoroughly 
interviewed by the doctors from the Department of 
Gastroenterology of Xijing Hospital; Xi’an in China and 
had no prior treatment or taken any medications prior 
the surgery. Violation any of those parameters were a 
major factor that would have excluded them from the 
studies. Immediately after the surgery, the excised colon 
tumor as well as the healthy colon control was sent to 
the Department of Pathology for pathological analysis 
and H&E staining (Supplementary Figure 6). Each 
Hematoxylin and Eosin staining (H&E) specimen was 
reviewed in China by board-certified pathologists (Dr. 
Peizhen Hu and Dr. Zengsan Li). Each adjacent normal 
tissue specimen was taken at the distance greater than 2cm 
from the actual tumor. Cases were staged according to the 
AJCC (American Joint Committee on Cancer staging 
system) [18]. Each tumor specimen weighed at least 60 mg 
and was typically under 200 mg. All of the specimens were 
formalin fixed and paraffin embedded (FFPE), histologic 
sections were obtained from top and bottom portions of 
each specimen. They confirmed that each tumor sample 
was histologically consistent with colon adenocarcinoma 
and that tumor cells were not contained in the adjacent 
normal specimen (Supplementary Figure 6).
RNA extraction from FFPE tissue
RecoverAllTM Total Nucleic Acid Isolation Kit was 
used according to the manufacturer’s protocol to isolate 
RNA from FFPE Tissues (AM1975, Ambion, Austin, 
TX) with optimization in order to obtain high quality 
materials for analysis. Briefly, 1 ml of 100% xylene was 
added to 3 different pieces of 20 mm thick FFPE sections 
and samples were incubated for 3 min at 50°C to remove 
traces of paraffin, and then centrifuged for 2 min to discard 
the xylene. Pellets were washed twice with 1 ml 100% 
ethanol. Tissues were digested with 200μl digestion 
buffer with protease K at 50°C overnight and then treated 
with DNase I. After washing, total RNA was eluted with 
distilled water, and RNA concentration was measured 
using the Nanodrop 2000 spectrophotometer. 
Quantitative real-time PCR
IScript™ cDNA Synthesis Kit 170-8891(Bio-
Rad Laboratories, Inc. CA) was used to make cDNA. 
Quantitative RT-PCR was performed on a ViiA™ 7 Real-
Time PCR System. Quantitative PCR for human NLRP1 
(Hs00248187_m1), NLRP3 (Hs00918082_m1), NLRP4 
(Hs00370499_m1), NLRP6 (Hs00373246_m1), NLRP12 
(Hs00536435_m1), NLRC3 (Hs01054716_m1), NLRC4 
(Hs00368367_m1), NLRC5 (Hs00260008_m1), NLRX1 
(Hs00226360_m1), NOD1 (Hs00196075_m1),  NOD2 
(Hs00223394_m1) and AIM2 (Hs00223394_m1) was 
performed by using TaqMan primer/probe sets and master 
mix (Applied Biosystems). To normalize the qPCR results, 
GAPDH (Hs02758991_g1), ACTB (Hs01060665_g1) 
and RNA18S (Hs03928985_g1) were chosen as reference 
genes. All samples were loaded in triplicates. Relative 
mRNA expression levels were compared via the 2-ΔΔCT 
methods or log-transformed [45]. 
 Statistical analysis
Data are presented as mean ± SEM. Ratios of real-
time PCR expression values of case matched normal 
and cancer tissues were used after normalization by the 
mean expression value of internal control genes: ACTB, 
GAPDH and 18S RNA. Differences between two sample 
groups were analyzed using the paired or unpaired 
Student’s t-test function of GraphPad Prism version 4 
software (Mann-Whitney unpaired test or Wilcoxon 
matched-pairs signed test). The association between 
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gene expression levels and clinical parameters was 
addressed by analysis of variance (ANOVA). p < 0.05 
was considered statistically significant. The Spearman 
correlation and linear regression analyses were performed 
using GraphPad. Interpretation of r value was conducted 
based on the following criteria: values greater than 0 and 
up to 1 indicated that two variables were changing in the 
same direction in a correlative fashion, while values below 
0 down and up to -1 indicated two variables that were 
changing in the opposite direction.
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